Date: 2015-10-16
Type of information: Licensing agreement
Compound: mesenchymal lineage adult stem cell product candidates
Company: Celgene (USA - NJ) Mesoblast (Australia)
Therapeutic area: Cancer - Oncology - Rare diseases - Inflammatory diseases - Transplantation
Type agreement: licensing equity placement
Action mechanism: stem cell therapy
Disease: acute graft-versus-host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
Details: * On April 13, 2015, Mesoblast announced that the Company has entered into an agreement with Celgene, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Pursuant to this agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields. In addition, Celgene has a six-month right of first refusal with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
Financial terms: Under the terms of the agreement, Celgene will purchase 15.3 million ordinary shares in Mesoblast for a consideration of A$58.5 million/US$45 million at a price of A$3.82 per share.
Latest news: * On October 16, 2015, Mesoblast announced that it has agreed with Celgene Corporation to extend for a period of six months Celgene’s right of first refusal with respect to Mesoblast’s proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and
organ transplant rejection.
